Elizabeth Plimack, MD, MS, FASCO, Fox Chase Cancer Center, comments on the long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study, the practice-changing impact of the latest results from KEYNOTE-564, and novel treatment investigations in non-clear cell RCC.
CheckMate 214, KEYNOTE-564, and Updates in Treatment Approaches to nccRCC
By Elizabeth Plimack, MD, MS, FASCO - Last Updated: May 1, 2024Related Posts
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
The combination therapy provided similar survival rates and toxicity in an older patient population.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.